Simcere Shuts Down Production in New Vaccine Subsidiary

Simcere Pharmaceutical Group (先声药业) has stopped a production line at its recently acquired vaccine subsidiary while it reviews quality control systems in the company. Simcere obtained majority control of Jiangsu Yanshen Biological Technology Stock Co. on October 24, 2009. Simcere said it soon discovered problems with quality control in the production of Yanshen's human-use rabies vaccine (vero cell). More details.., Stock Symbol: (NYSE: SCR)